The aim of the EuroSpA Research Collaboration Network

The aim of the EuroSpA Research Collaboration Network (RCN) is to jointly address research questions in SpA including, but not limited to, real world effectiveness and safety profiles of biologic therapies. This is done by retrospectively and prospectively collecting real life patient data from European registers.

The collaboration promotes opportunities to identify unmet needs in the treatment of SpA patients by utilizing high-quality data from existing patient registries.

Our aims are in line with the EMA initiative for patient registries and are consistent with discussions at the EMA workshop “How to make better use of patient registries to collect high-quality data on medicines” held in London on October 28th, 2016 in London.

EuroSpA RCN Scope

Currently the collaboration consists of 17 registries (see map).

There is a recognized openness to include other interested registries and to other parties such as health authorities (EMA and local regulatory bodies) and patient organizations, although the extent of their involvement will need to be further defined.


Novartis Pharma AG for supporting the EuroSpA collaboration.
UCB Biopharma SRL for supporting the EuroSpA collaboration.

Registries that contribute data to the collaboration

ARC (Netherlands)

ATTRA (Czech Republic)


Biorx.si (Slovenia)

BSRBR-AS (United Kingdom)

DANBIO (Denmark)

ESTONIA (ERS Biologic Therapy Register)

GISEA (Italy)

ICEBIO (Iceland)

NOR-DMARD (Norway)

RABBIT-SpA (Germany)

Reuma.pt (Portugal)

ROBFIN (Finland)

Romanian registry of Rheumatic Diseases

SCQM (Switzerland)

SRQ (Sweden)

TURKBIO (Turkey)

The most recent EuroSpA publications

EuroSpA publication E.1

By |November 6th, 2023|Categories: News|

Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration Click here to access [...]

Comments Off on EuroSpA publication E.1

EuroSpA publication 1.4

By |November 6th, 2023|Categories: News|

Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching Click here to [...]

Comments Off on EuroSpA publication 1.4

EuroSpA publication A2.1

By |November 6th, 2023|Categories: News|

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe Click [...]

Comments Off on EuroSpA publication A2.1

EuroSpA publication 4.1

By |November 6th, 2023|Categories: News|

Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries Click here to [...]

Comments Off on EuroSpA publication 4.1

EuroSpA publication 2.2

By |November 6th, 2023|Categories: News|

One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment Click here to access [...]

Comments Off on EuroSpA publication 2.2

To see full list, please click Publications in top menu

EuroSpA meetings

EuroSpA Scientific Committee consists of representatives from the 17 participating registries, who meets for hybrid meetings twice yearly in Copenhagen and online.

Go to Top